Teva Pharmaceutical Industries Stock Forecast, Price & News

Teva Pharmaceutical Industries (NYSE:TEVA) Frequently Asked Questions

Is Teva Pharmaceutical Industries a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teva Pharmaceutical Industries in the last year. There are currently 4 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Teva Pharmaceutical Industries stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TEVA, but not buy additional shares or sell existing shares.
View analyst ratings for Teva Pharmaceutical Industries or view top-rated stocks.

How has Teva Pharmaceutical Industries' stock price been impacted by COVID-19 (Coronavirus)?

Teva Pharmaceutical Industries' stock was trading at $9.01 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, TEVA shares have decreased by 6.1% and is now trading at $8.46.
View which stocks have been most impacted by COVID-19.

When is Teva Pharmaceutical Industries' next earnings date?

Teva Pharmaceutical Industries is scheduled to release its next quarterly earnings announcement on Wednesday, February 9th 2022.
View our earnings forecast for Teva Pharmaceutical Industries.

How were Teva Pharmaceutical Industries' earnings last quarter?

Teva Pharmaceutical Industries Limited (NYSE:TEVA) issued its earnings results on Wednesday, October, 27th. The company reported $0.59 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.65 by $0.06. The business had revenue of $3.89 billion for the quarter, compared to analyst estimates of $4.05 billion. Teva Pharmaceutical Industries had a trailing twelve-month return on equity of 23.53% and a net margin of 4.47%. The firm's revenue was down 2.8% compared to the same quarter last year. During the same period in the prior year, the company posted $0.56 EPS.
View Teva Pharmaceutical Industries' earnings history.

What guidance has Teva Pharmaceutical Industries issued on next quarter's earnings?

Teva Pharmaceutical Industries updated its FY 2021 earnings guidance on Wednesday, November, 3rd. The company provided EPS guidance of $2.500-$2.700 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.580. The company issued revenue guidance of $16 billion-$16.40 billion, compared to the consensus revenue estimate of $16.30 billion.

What price target have analysts set for TEVA?

4 brokerages have issued 12 month price targets for Teva Pharmaceutical Industries' shares. Their forecasts range from $10.00 to $14.00. On average, they expect Teva Pharmaceutical Industries' share price to reach $11.50 in the next year. This suggests a possible upside of 35.9% from the stock's current price.
View analysts' price targets for Teva Pharmaceutical Industries or view top-rated stocks among Wall Street analysts.

Who are Teva Pharmaceutical Industries' key executives?

Teva Pharmaceutical Industries' management team includes the following people:

• Kåre Schultz, President, Chief Executive Officer & Director
• Eric Drapé, Executive Vice President-Global Operations
• Eli Kalif, Chief Financial Officer & Executive Vice President
• Hafrun Fridriksdottir, Executive VP-Global Research & Development
• Lori A. Queisser, Senior Vice President & Global Compliance Officer

What is Kåre Schultz's approval rating as Teva Pharmaceutical Industries' CEO?

158 employees have rated Teva Pharmaceutical Industries CEO Kåre Schultz on Glassdoor.com. Kåre Schultz has an approval rating of 90% among Teva Pharmaceutical Industries' employees.

Who are some of Teva Pharmaceutical Industries' key competitors?

Some companies that are related to Teva Pharmaceutical Industries include MERCK Kommanditgesellschaft auf Aktien (MKGAF), BeiGene (BGNE), Astellas Pharma (ALPMY), Genmab A/S (GMAB), Genmab A/S (GNMSF), Shiseido (SSDOY), Royalty Pharma (RPRX), Horizon Therapeutics Public (HZNP), Catalent (CTLT), Takeda Pharmaceutical (TKPYY), Alnylam Pharmaceuticals (ALNY), UCB (UCBJF), BioMarin Pharmaceutical (BMRN), Viatris (VTRS) and Elanco Animal Health (ELAN).
View all of TEVA's competitors.

What other stocks do shareholders of Teva Pharmaceutical Industries own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Teva Pharmaceutical Industries investors own include General Electric (GE), AT&T (T), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), Bank of America (BAC), Micron Technology (MU), Gilead Sciences (GILD), Johnson & Johnson (JNJ) and Cisco Systems (CSCO).

What is Teva Pharmaceutical Industries' stock symbol?

Teva Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA."

Who are Teva Pharmaceutical Industries' major shareholders?

Teva Pharmaceutical Industries' stock is owned by many different institutional and retail investors. Top institutional investors include Capital Research Global Investors (10.78%), BlackRock Inc. (3.68%), Migdal Insurance & Financial Holdings Ltd. (1.93%), Menora Mivtachim Holdings LTD. (1.77%), Phoenix Holdings Ltd. (1.28%) and Harel Insurance Investments & Financial Services Ltd. (0.91%). Company insiders that own Teva Pharmaceutical Industries stock include Brendan P O'grady, David Matthew Stark, Deborah A Griffin, Eric Drape, Hafrun Fridriksdottir, Mark Sabag, Pharmaceutical Co Ltd Takeda, Richard Daniell and Rosemary A Crane.
View institutional ownership trends for Teva Pharmaceutical Industries.

Which major investors are selling Teva Pharmaceutical Industries stock?

TEVA stock was sold by a variety of institutional investors in the last quarter, including Capital World Investors, Capital Research Global Investors, Renaissance Technologies LLC, Psagot Value Holdings Ltd., Psagot Value Holdings Ltd., Camber Capital Management LP, Citigroup Inc., and AustralianSuper Pty Ltd. Company insiders that have sold Teva Pharmaceutical Industries company stock in the last year include David Matthew Stark, Eric Drape, Hafrun Fridriksdottir, Mark Sabag, and Pharmaceutical Co Ltd Takeda.
View insider buying and selling activity for Teva Pharmaceutical Industries or view top insider-selling stocks.

Which major investors are buying Teva Pharmaceutical Industries stock?

TEVA stock was bought by a variety of institutional investors in the last quarter, including Menora Mivtachim Holdings LTD., Beck Mack & Oliver LLC, Phoenix Holdings Ltd., Migdal Insurance & Financial Holdings Ltd., Citadel Advisors LLC, Deutsche Bank AG, Caisse DE Depot ET Placement DU Quebec, and BlackRock Inc..
View insider buying and selling activity for Teva Pharmaceutical Industries or or view top insider-buying stocks.

How do I buy shares of Teva Pharmaceutical Industries?

Shares of TEVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Teva Pharmaceutical Industries' stock price today?

One share of TEVA stock can currently be purchased for approximately $8.46.

How much money does Teva Pharmaceutical Industries make?

Teva Pharmaceutical Industries has a market capitalization of $9.33 billion and generates $16.66 billion in revenue each year. The company earns $-3.99 billion in net income (profit) each year or $0.66 on an earnings per share basis.

How many employees does Teva Pharmaceutical Industries have?

Teva Pharmaceutical Industries employs 40,216 workers across the globe.

What is Teva Pharmaceutical Industries' official website?

The official website for Teva Pharmaceutical Industries is www.tevapharm.com.

Where are Teva Pharmaceutical Industries' headquarters?

Teva Pharmaceutical Industries is headquartered at 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131.

How can I contact Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries' mailing address is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. The company can be reached via phone at (723) 926-7267, via email at [email protected], or via fax at 972-3923-4050.